Baseline characteristics

A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia · Source last updated 2016-06-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      11

   units

   Participants

groups

1. description

   All participants enrolled. 5-Azacitidine: Administered on Days 1-7 of each Cycle. Subcutaneous administration: To provide a homogeneous suspension, the contents of the syringe must be re-suspended by inverting the syringe 2-3 times and vigorously rolling the syringe between the palms for 30 seconds immediately prior to administration. The 5-azacitidine suspension is administered subcutaneously. Intravenous Administration: 5-Azacitidine solution is administered intravenously. Administer the total dose over a period of 10-40 minutes.

   id

   BG000

   title

   All Patients

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            lower Limit

            56

            upper Limit

            85

            value

            69

   dispersion Type

   FULL_RANGE

   param Type

   MEDIAN

   title

   Age, Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            5

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            6

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice